This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brommage, R. Articles by Jerome, C. P. Search for Related Content PubMed PubMed Citation Articles by Brommage, R. Articles by Jerome, C. P. Pubmed/NCBI databases OMIM Compound via MeSH Substance via MeSH Hazardous Substances DB CALCIUM COMPOUNDS CALCIUM, ELEMENTAL PARATHYROID HORMONE

Daily Treatment with Human Recombinant Parathyroid Hormone-(1–34), LY333334, for 1 Year Increases Bone Mass in Ovariectomized Monkeys¹

Department of Pathology, Wake Forest University School of Medicine (R.B., C.E.H., C.J.L., M.W.S., C.P.J.), Winston-Salem, North Carolina 27157-1040; and Lilly Research Laboratories (J.M.H.), Indianapolis, Indiana 46285

Address all correspondence and requests for reprints to: Robert Brommage, Ph.D., Section on Comparative Medicine, Department of Pathology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, North Carolina 27157-1040. E-mail: brommage{at}wfubmc.edu

PTH stimulates bone formation to increase bone mass and strength in rats and humans. The aim of this study was to determine the skeletal effects of recombinant human PTH-(1–34) [rhPTH-(1–34)] in monkeys, as monkey bone remodeling and structure are similar to those in human bone.

Adult female cynomolgus monkeys were divided into sham-vehicle (n = 21), ovariectomized (OVX)-vehicle (n = 20), and OVX groups given daily sc injections of rhPTH-(1–34) at 1 (n = 39) or 5 (n = 41) µg/kg for 12 months. Whole body bone mineral content was measured, as was bone mineral density (BMD) in the spine, proximal tibia, midshaft radius, and distal radius. Serum and urine samples were also analyzed. rhPTH-(1–34) treatment did not influence serum ionized Ca levels or urinary Ca excretion, but depressed endogenous PTH while increasing serum calcitriol levels. Compared to that in the OVX group, the higher dose of rhPTH-(1–34) increased spine BMD by 14.3%, whole body bone mineral content by 8.6%, and proximal tibia BMD by 10.8%. Subregion analyses suggested that the anabolic effect of rhPTH-(1–34) on the proximal tibia was primarily in cancellous bone. Similar, but less dramatic, effects on BMD were observed with the lower dose of rhPTH-(1–34). Daily sc rhPTH-(1–34) treatment for 1 yr increases BMD in ovariectomized monkeys without inducing sustained hypercalcemia or hypercalciuria.

This article has been cited by other articles:

				Y. Xue, A. C. Karaplis, G. N. Hendy, D. Goltzman, and D. Miao Exogenous 1,25-Dihydroxyvitamin D3 Exerts a Skeletal Anabolic Effect and Improves Mineral Ion Homeostasis in Mice that Are Homozygous for Both the 1{alpha}-Hydroxylase and Parathyroid Hormone Null Alleles Endocrinology, October 1, 2006; 147(10): 4801 - 4810. [Abstract] [Full Text] [PDF]

				E. P. Paschalis, E. V. Glass, D. W. Donley, and E. F. Eriksen Bone Mineral and Collagen Quality in Iliac Crest Biopsies of Patients Given Teriparatide: New Results from the Fracture Prevention Trial J. Clin. Endocrinol. Metab., August 1, 2005; 90(8): 4644 - 4649. [Abstract] [Full Text] [PDF]

				K. A Cappuzzo and J. C Delafuente Teriparatide for Severe Osteoporosis Ann. Pharmacother., February 1, 2004; 38(2): 294 - 302. [Abstract] [Full Text] [PDF]

				I. Ahmed, D. Gesty-Palmer, M. K. Drezner, and L. M. Luttrell Transactivation of the Epidermal Growth Factor Receptor Mediates Parathyroid Hormone and Prostaglandin F2{alpha}-Stimulated Mitogen-Activated Protein Kinase Activation in Cultured Transgenic Murine Osteoblasts Mol. Endocrinol., August 1, 2003; 17(8): 1607 - 1621. [Abstract] [Full Text] [PDF]

				Y. L. Ma, H. U. Bryant, Q. Zeng, A. Schmidt, J. Hoover, H. W. Cole, W. Yao, W. S. S. Jee, and M. Sato New Bone Formation with Teriparatide [Human Parathyroid Hormone-(1-34)] Is Not Retarded by Long-Term Pretreatment with Alendronate, Estrogen, or Raloxifene in Ovariectomized Rats Endocrinology, May 1, 2003; 144(5): 2008 - 2015. [Abstract] [Full Text] [PDF]

				J.-J. Body, G. A. Gaich, W. H. Scheele, P. M. Kulkarni, P. D. Miller, A. Peretz, R. K. Dore, R. Correa-Rotter, A. Papaioannou, D. C. Cumming, et al. A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1-34)] with Alendronate in Postmenopausal Women with Osteoporosis J. Clin. Endocrinol. Metab., October 1, 2002; 87(10): 4528 - 4535. [Abstract] [Full Text] [PDF]

				M. Sato, J. Vahle, A. Schmidt, M. Westmore, S. Smith, E. Rowley, and L. Y. Ma Abnormal Bone Architecture and Biomechanical Properties with Near-Lifetime Treatment of Rats with PTH Endocrinology, September 1, 2002; 143(9): 3230 - 3242. [Abstract] [Full Text] [PDF]

				J. L. Vahle, M. Sato, G. G. Long, J. K. Young, P. C. Francis, J. A. Engelhardt, M. S. Westmore, Y. L. Ma, and J. B. Nold Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety Toxicol Pathol, April 1, 2002; 30(3): 312 - 321. [Abstract] [PDF]

				L. Jin, S. L. Briggs, S. Chandrasekhar, N. Y. Chirgadze, D. K. Clawson, R. W. Schevitz, D. L. Smiley, A. H. Tashjian, and F. Zhang Crystal Structure of Human Parathyroid Hormone 1-34 at 0.9-A Resolution J. Biol. Chem., August 25, 2000; 275(35): 27238 - 27244. [Abstract] [Full Text] [PDF]